179 related articles for article (PubMed ID: 8637714)
1. Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin.
Zhang L; Hung MC
Oncogene; 1996 Feb; 12(3):571-6. PubMed ID: 8637714
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
[TBL] [Abstract][Full Text] [Related]
3. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
Zhang L; Chang CJ; Bacus SS; Hung MC
Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells.
Lei W; Mayotte JE; Levitt ML
Anticancer Res; 1999; 19(1A):221-8. PubMed ID: 10226546
[TBL] [Abstract][Full Text] [Related]
5. Basic science of HER-2/neu: a review.
Hung MC; Lau YK
Semin Oncol; 1999 Aug; 26(4 Suppl 12):51-9. PubMed ID: 10482194
[TBL] [Abstract][Full Text] [Related]
6. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells.
Tsai CM; Levitzki A; Wu LH; Chang KT; Cheng CC; Gazit A; Perng RP
Cancer Res; 1996 Mar; 56(5):1068-74. PubMed ID: 8640763
[TBL] [Abstract][Full Text] [Related]
8. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
9. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.
Zhang L; Lau YK; Xi L; Hong RL; Kim DS; Chen CF; Hortobagyi GN; Chang C; Hung MC
Oncogene; 1998 Jun; 16(22):2855-63. PubMed ID: 9671406
[TBL] [Abstract][Full Text] [Related]
11. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines.
Tsai CM; Chang KT; Wu LH; Chen JY; Gazdar AF; Mitsudomi T; Chen MH; Perng RP
Cancer Res; 1996 Jan; 56(1):206-9. PubMed ID: 8548764
[TBL] [Abstract][Full Text] [Related]
12. Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu.
Hong RL; Spohn WH; Hung MC
Clin Cancer Res; 1999 Jul; 5(7):1884-91. PubMed ID: 10430096
[TBL] [Abstract][Full Text] [Related]
13. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
14. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner.
Bos M; Mendelsohn J; Kim YM; Albanell J; Fry DW; Baselga J
Clin Cancer Res; 1997 Nov; 3(11):2099-106. PubMed ID: 9815602
[TBL] [Abstract][Full Text] [Related]
15. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
Bhargava R; Naeem R; Marconi S; Luszcz J; Garb J; Gasparini R; Otis CN
Hum Pathol; 2001 Dec; 32(12):1344-50. PubMed ID: 11774167
[TBL] [Abstract][Full Text] [Related]
19. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells.
You XL; Yen L; Zeng-Rong N; Al Moustafa AE; Alaoui-Jamali MA
Oncogene; 1998 Dec; 17(24):3177-86. PubMed ID: 9872333
[TBL] [Abstract][Full Text] [Related]
20. Expression of activated c-erbB-2 oncogene induces sensitivity to cisplatin in human gallbladder adenocarcinoma cells.
Boudny V; Murakami Y; Nakano S; Niho Y
Anticancer Res; 1999; 19(6B):5203-6. PubMed ID: 10697535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
